Luspatercept

The FDA approved luspatercept-aamt as first-line treatment for anemia among certain adults with myelodysplastic syndrome.

Healio spoke with David Andrew Sallman, MD, about recent advancements and approvals in myelodysplastic syndrome.

In this video, Ruben Mesa, MD, discussed the backstory behind a study presented at ASCO Annual Meeting, examining the effect of luspatercept on patients with myelofibrosis suffering from anemia.

In this video, Ruben Mesa, MD, discussed the results of the phase 3 COMMANDS study, pertaining to low-risk myelodysplastic syndrome, presented at ASCO Annual Meeting.

In this video, Idoroenyi Amanam, MD, discussed a study presented at ASCO Annual Meeting, examining the use of luspatercept in the treatment of anemia in myelofibrosis patients.

In this video, Aaron T. Gerds, MD, MS, discussed the results of the phase 3 COMMANDS study, pertaining to low-risk myelodysplastic syndrome, presented at ASCO Annual Meeting.

In this video, Aaron T. Gerds, MD, MS, discussed the backstory behind a study he presented at ASCO Annual Meeting, examining the effect of luspatercept on patients with myelofibrosis suffering from anemia.

In this video, Eunice Wang, MD, discussed the results of the phase 3 COMMANDS study, pertaining to low-risk myelodysplastic syndrome, presented at ASCO Annual Meeting.

Treatment with luspatercept vs. epoetin alfa nearly doubled the number of patients with lower-risk myelodysplastic syndrome who no longer required red blood cell transfusions for anemia, results of the phase 3 COMMANDS trial showed.

The FDA announced several regulatory actions the past few weeks.